AgingResearch.NewsJoin free

NeuExcell

CompanyChina

NeuExcell develops 2 assets, the furthest in human trials (NXL-001 in Alzheimer's disease). Mostly gene therapy acting on NEUROD1; based in China.

2
Assets
Furthest stage
Human trials
Raised
US$10m
0
Trials
0
Signals

Pipeline

2

  • NXL-001

    Human trials, Alzheimer's disease

  • NXL-004

    Delivers NeuroD1 via AAV6 to reprogram glioma cells into non-dividing neuron-like cells, inducing cell death and immune activation.

    Human trials, Gene therapy, NEUROD1, recurrent malignant glioma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Funding rounds and grants2
  • People7
  • Similar companies6

Intelligence